13 completed, 5 terminated, 1 active not recruiting. 11 Phase 2, 7 Phase 1, 2 Not applicable, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 8, Terminated 3 |
| Phase 1 | 7 | Terminated 4, Completed 3 |
| Not applicable | 2 | Completed 2 |
| Early Phase 1 | 1 | Completed 1 |
Follow Stage I Cutaneous T-Cell Non-Hodgkin Lymphoma: new trials by email Literature Review of Stage I Cutaneous T-Cell Non-Hodgkin Lymphoma trials Research Report on Stage I Cutaneous T-Cell Non-Hodgkin Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma Brentuximab Vedotin, Laboratory Biomarker Analysis, Lenalidomide - Lymphomatoid Papulosis, Primary Cutaneous Anaplastic Large Cell Lymphoma | Phase 2 | Completed | John Reneau | 26 | 2018-03-16 | 2026-08-13 |
| Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma romidepsin, lenalidomide, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 2 | Completed | Northwestern University | 30 | 2015-06-11 | 2026-06-12 |
| Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant busulfan, etoposide, cyclophosphamide - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Early Phase 1 | Completed | Case Comprehensive Cancer Center | 33 | 2014-03-01 | 2015-08-13 |
| Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma silicon phthalocyanine 4, photodynamic therapy, pharmacological study - Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome | Phase 1 | Completed | Kevin Cooper MD | 11 | 2013-04-01 | 2019-05-16 |
| Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma carfilzomib, romidepsin, laboratory biomarker analysis - Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome | Phase 1 | Terminated | Northwestern University | 7 | 2013-03-22 | 2019-08-29 |
| Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas brentuximab vedotin, rituximab, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 / Phase 2 | Terminated | Northwestern University | 20 | 2013-03-05 | 2021-09-01 |
| Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant tetanus-CMV fusion peptide vaccine, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 | Completed | City of Hope Medical Center | 36 | 2012-10-29 | 2024-04-02 |
| Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant infection prophylaxis and management, laboratory biomarker analysis, flow cytometry - Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia | Active not recruiting | City of Hope Medical Center | 153 | 2011-01-11 | 2026-10-22 | |
| Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies deferasirox, laboratory biomarker analysis, enzyme-linked immunosorbent assay - Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Wake Forest University Health Sciences | 16 | 2011-01-01 | 2018-09-07 |
| Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer massage therapy, questionnaire administration, quality-of-life assessment - Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia | Not applicable | Completed | Wake Forest University Health Sciences | 80 | 2010-04-01 | 2018-07-02 |
| Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer rituximab, mycophenolate mofetil, tacrolimus - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Terminated | University of Nebraska | 20 | 2009-12-10 | 2023-09-06 |
| Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma vorinostat, rituximab, ifosfamide - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 / Phase 2 | Completed | University of Washington | 29 | 2007-12-01 | 2017-05-25 |
| Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer beclomethasone dipropionate, placebo, tacrolimus - Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 140 | 2007-04-01 | 2021-02-03 |
| Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer fludarabine phosphate, total-body irradiation, mycophenolate mofetil - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Fred Hutchinson Cancer Center | 150 | 2004-04-01 | 2020-01-29 |
| Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides aldesleukin, recombinant interleukin-12, laboratory biomarker analysis - Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 46 | 2002-09-01 | 2013-01-16 |
| Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies alemtuzumab, fludarabine phosphate, total-body irradiation - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q) | Phase 2 | Completed | Fred Hutchinson Cancer Center | 60 | 2001-11-01 | 2020-01-29 |
| 506U78 in Treating Patients With Lymphoma nelarabine - Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 74 | 2000-05-01 | 2013-01-16 |
| Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer fludarabine phosphate, total-body irradiation, peripheral blood stem cell transplantation - Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia | Not applicable | Completed | Fred Hutchinson Cancer Center | 5 | 1999-11-01 | 2017-05-24 |
| O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma O6-benzylguanine, carmustine, laboratory biomarker analysis - Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 20 | 1999-04-01 | 2013-01-11 |
Lymphoma, T-Cell, Cutaneous (19) · Mycosis Fungoides (17) · Sezary Syndrome (17) · Burkitt Lymphoma (12) · Leukemia, Lymphocytic, Chronic, B-Cell (12) · Lymphoma, Extranodal NK-T-Cell (12) · Lymphoma, Large B-Cell, Diffuse (12) · Lymphoma, Large-Cell, Anaplastic (12) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (12) · Immunoblastic Lymphadenopathy (11) · Lymphoma, B-Cell, Marginal Zone (11) · Lymphoma, Follicular (11) · Lymphoma, Mantle-Cell (11) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (11) · Hodgkin Disease (10)
Hemic and Lymphatic Diseases (19) · Immune System Diseases (19) · Immunoproliferative Disorders (19) · Lymphatic Diseases (19) · Lymphoproliferative Disorders (19) · Neoplasms (19) · Neoplasms by Histologic Type (19) · Lymphoma (18) · Lymphoma, T-Cell (18) · Hematologic Diseases (13) · Leukemia, Lymphoid (13) · Blood Protein Disorders (12) · Cardiovascular Diseases (12) · Chronic Disease (12) · DNA Virus Infections (12)
Mycophenolic Acid (4) · Peripheral Blood Stem Cell Transplantation (4) · Whole-Body Irradiation (4) · fludarabine phosphate (4) · Rituximab (3) · Tacrolimus (3) · Brentuximab Vedotin (2) · Busulfan (2) · Cyclophosphamide (2) · Cyclosporine (2) · Etoposide (2) · Lenalidomide (2) · Therapeutics (2) · romidepsin (2) · 1-phenyl-3,3-dimethyltriazene (1)
Fred Hutchinson Cancer Center (4) · National Cancer Institute (NCI) (3) · Northwestern University (3) · City of Hope Medical Center (2) · Wake Forest University Health Sciences (2) · Case Comprehensive Cancer Center (1) · John Reneau (1) · Kevin Cooper MD (1) · University of Nebraska (1) · University of Washington (1)
United States (19) · Italy (2)
Ryotaro Nakamura (2) · Adam Petrich, MD (1) · Alain Rook (1) · Ann Woolfrey (1) · Barbara Pro, MD (1) · Brenda Sandmaier (1) · Brian Hill, MD (1) · David Maloney (1) · Elma Baron, MD (1) · Janet Tooze, PhD (1) · John Reneau, MD (1) · Jonathan Moreira, MD (1) · Kevin Cooper (1) · Lihua Budde (1) · Mary Ann Knovich, MD (1)
PMID 18698002, PMID 19900571, PMID 22250189, PMID 26853648, PMID 30562587, PMID 32499241, PMID 32632956, PMID 37327113
P30CA015704 (3), P01CA018029 (2), P01CA078902 (1), P30CA036727 (1), P30CA043703 (1), P30CA060553 (1), R01CA089442 (1), U01CA062502 (1), U10CA031946 (1)